Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KPRX 
Kiora Pharmaceuticals Inc (KPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: KPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11
1 Year Target Price $11
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.25% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.27M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 2 | Beta -0.67 | 52 Weeks Range 2.25 - 4.18 | Updated Date 10/13/2025 |
52 Weeks Range 2.25 - 4.18 | Updated Date 10/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -16.35% | Return on Equity (TTM) -43.39% |
Valuation
Trailing PE - | Forward PE 2.41 | Enterprise Value -10587617 | Price to Sales(TTM) 363.74 |
Enterprise Value -10587617 | Price to Sales(TTM) 363.74 | ||
Enterprise Value to Revenue 569.41 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 3433491 | Shares Floating 2929523 |
Shares Outstanding 3433491 | Shares Floating 2929523 | ||
Percent Insiders 3.19 | Percent Institutions 25.28 |
Upturn AI SWOT
Kiora Pharmaceuticals Inc
Company Overview
History and Background
Kiora Pharmaceuticals, formerly Ophthalmology Limited, is a clinical-stage biotechnology company focused on developing and commercializing therapies for ophthalmic diseases. Founded to address unmet needs in vision restoration, the company is working to improve the lives of patients with sight-threatening and debilitating eye diseases. Originally focused exclusively on ophthalmology and now broadening focus.
Core Business Areas
- Retinal Disease Therapies: Kiora develops and researches drugs to treat retinal diseases, which is their main area of business and focus on commercializing products here.
- Investigational Drug Delivery System: Kiora develops the AB103 systemic investigational drug, is a next-generation photosensitive retinal protection molecule developed to treat inherited and age-related retinal diseases, including retinitis pigmentosa and Stargardt disease.
Leadership and Structure
Mark L Baum is the President & CEO and is on the Board of Directors. Eric Daniels is the Cheif Financial Officer. The company operates with a structure typical of a biotechnology firm, comprising research and development, clinical operations, and corporate management divisions. The Board of Directors includes members with expertise in pharmaceuticals, finance, and healthcare management.
Top Products and Market Share
Key Offerings
- AB103: Kiora's lead investigational product, AB103, is focused on treating inherited and age-related retinal diseases. Market share is currently 0%, as it's in clinical development. Competitors in retinal disease therapies include Genentech (Lucentis, Vabysmo), Regeneron (Eylea), and Apellis (Syfovre).
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical industry is driven by an aging population, increasing prevalence of diabetes, and technological advancements in drug delivery and treatment modalities. It's a growing market due to the increasing number of people suffering from eye diseases.
Positioning
Kiora aims to compete by focusing on specific retinal diseases with significant unmet needs, with a innovative investigational drug delivery system, positioning themselves for niche markets.
Total Addressable Market (TAM)
The global ophthalmology market is expected to reach hundreds of billions in the near future. Kiora's positioning to address unmet needs will allow it to capture some of this total addressable market.
Upturn SWOT Analysis
Strengths
- Novel drug delivery technology
- Focus on specific retinal diseases
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage clinical development
- Dependence on a single product (AB103)
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- REGN
- LLY
- NVS
Competitive Landscape
Kiora is a small player compared to established pharmaceutical giants. Its advantage lies in its novel investigational drug delivery system. Kiora will need to partner with a larger player in order to achieve market share. The company's ability to do this is at risk.
Growth Trajectory and Initiatives
Historical Growth: Kiora's historical growth has been limited by its development stage. Most spending has been in R&D.
Future Projections: Future projections depend on the success of AB103 in clinical trials and potential partnerships. Analyst estimates are highly speculative at this stage.
Recent Initiatives: Recent initiatives include advancing AB103 through clinical trials and seeking strategic partnerships.
Summary
Kiora Pharmaceuticals is a high-risk, high-reward clinical-stage biotechnology company focused on retinal diseases. Its strength lies in its novel investigational drug delivery system. However, its weaknesses include limited financial resources and dependence on the success of AB103. The company needs to secure partnerships and demonstrate positive clinical trial results to achieve long-term viability. If they are unable to deliver on clinical trials they will quickly run out of funding to stay afloat.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (where available, but speculative for micro-caps)
- Market research reports
Disclaimers:
This analysis is based on publicly available information and represents an assessment of Kiora Pharmaceuticals Inc. It should not be considered financial advice. The biotechnology industry is inherently risky, and investment decisions should be made with careful consideration of all relevant factors.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiora Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Encinitas, CA, United States | ||
IPO Launch date 2015-07-31 | President, CEO & Director Dr. Brian M. Strem Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.kiorapharma.com |
Full time employees 12 | Website https://www.kiorapharma.com | ||
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.